Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 35.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,326 shares of the specialty pharmaceutical company's stock after selling 14,350 shares during the period. Wellington Management Group LLP's holdings in Supernus Pharmaceuticals were worth $821,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in SUPN. GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 398 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $47,000. Innealta Capital LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after acquiring an additional 352 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in Supernus Pharmaceuticals in the second quarter valued at $72,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded down $0.34 during trading on Friday, reaching $35.43. The company's stock had a trading volume of 1,057,620 shares, compared to its average volume of 438,825. The business's fifty day moving average price is $35.61 and its 200-day moving average price is $32.16. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 33.11 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter last year, the company posted ($0.29) earnings per share. The business's revenue was up 14.2% on a year-over-year basis. As a group, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now owns 926,172 shares of the company's stock, valued at $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now directly owns 8,200 shares of the company's stock, valued at $303,236. This represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company's stock.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several research reports. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.